Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility

Circulation

Volumn 122, Issue 5, 2010, Pages 470-477

  Vergeer, Menno ^a   Boekholdt, S Matthijs ^a   Sandhu, Manjinder S ^b,c,d   Ricketts, Sally L ^b   Wareham, Nicholas J ^c   Brown, Morris J ^e   Faire, Ulf De ^f   Leander, Karin ^f   Gigante, Bruna ^f   Kavousi, Maryam ^g   Hofman, Albert ^g   Uitterlinden, Andre G ^g   Van Duijn, Cornelia M ^g   Witteman, Jacqueline C M ^g   Jukema, J Wouter ^h   Schadt, Eric E ⁱ   Van Der Schoot, Ellen ^j   Kastelein, John J P ^a   Khaw, Kay Tee ^b   Dullaart, Robin P F ^k   Van Tol, Arie ^g,k   Trip, Mieke D ^a   Dallinga Thie, Geesje M ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ PACIFIC BIOSCIENCES   (United States)

^j SANQUIN RESEARCH   (Netherlands)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

atherosclerosis; genetics; lipoproteins, HDL; PLTP protein, human

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PARTICLE SIZE; PHOSPHOLIPID TRANSFER PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 77955423268     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.912519     Document Type: Article

References (47)

1. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
2. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
3. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299: 2524-2532.
4. Wild S, Byrne CD. Time to rethink high-density lipoprotein? Heart. 2008;94:692-694.
5. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J, Rye KA. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem. 2001;276: 26898-26905.
6. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J. 1996;313:275-282.
7. Rye KA, Barter PJ. Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor. Biochim Biophys Acta. 1986;875:429-438.
8. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103:907-914.
9. Vergeer M, Dallinga-Thie GM, Dullaart RPF, van Tol A. Evaluation of phospholipid transfer protein as a therapeutic target. Fut Lipidol. 2008; 3:327-335.
10. De Vries R, Dallinga-Thie GM, Smit A, Wolffenbuttel B, Van Tol A, Dullaart RP, Abreu E. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia. 2006;49:398-404. (Pubitemid 43185411)
11. Schlitt A, Blankenberg S, Bickel C, Lackner KJ, Heine GH, Buerke M, Werdan K, Maegdefessel L, Raaz U, Rupprecht HJ, Munzel T, Jiang XC. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. J Lipid Res. 2009;50:723-729.
12. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, Jiang XC. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2003; 23:1857-1862.
13. Schgoer W, Mueller T, Jauhiainen M, Wehinger A, Gander R, Tancevski I, Salzmann K, Eller P, Ritsch A, Haltmayer M, Ehnholm C, Patsch JR, Foeger B. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 2008;196:219-226.
14. Engler MB, Pullinger CR, Malloy MJ, Natanzon Y, Kulkarni MV, Song J, Eng C, Huuskonen J, Rivera C, Poon A, Bensley M, Sehnert A, Zellner C, Kane J, Aouizerat BE. Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia. Metabolism. 2008;57:1719-1724.
15. Bosse Y, Bouchard L, Despres JP, Bouchard C, Perusse L, Vohl MC. Haplotypes in the phospholipid transfer protein gene are associated with obesity-related phenotypes: the Quebec Family Study. Int J Obes Relat Metab Disord. 2005;29:1338-1345.
16. DALI Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24:1335-1341.
17. De Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BHR, van Tol A, Dullaart RPF. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes. 2005;54:3554-3559.
18. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, De Bakker PIW, O'Donnell CJ, Chambers JC, Kooner JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56-65.
19. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. Br J Cancer. 1999;80:95-103.
20. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med. 2004;117: 390-397.
21. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O'Shaughnessy KM, Brown MJ. A common variant of the endothelial nitric oxide synthase (Glu2983Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999;100:1515-1520.
22. Koessler T, Oestergaard MZ, Song H, Tyrer J, Perkins B, Dunning AM, Easton DF, Pharoah PD. Common variants in mismatch repair genes and risk of colorectal cancer. Gut. 2008;57:1097-1101.
23. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol. 2009;24:553-572.
24. Reuterwall C, Hallqvist J, Ahlbom A, De Faire U, Diderichsen F, Hogstedt C, Pershagen G, Theorell T, Wiman B, Wolk A. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study: the SHEEP Study Group. J Intern Med. 1999;246:161-174.
25. The International HapMap Project. Nature. 2003;426:789-796.
26. De Bakker PIW, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet. 2005;37: 1217-1223.
27. Dallinga-Thie GM, van Tol A, Hattori H, Rensen PCN, Sijbrands EJG, for the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes. 2006;55:1491-1496. (Pubitemid 44195392)
28. Perusse M, Pascot A, Despres JP, Couillard C, Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electro-phoresis using whole plasma. J Lipid Res. 2001;42:1331-1334.
29. El-Harchaoui K, Arsenault BJ, Franssen R, Despres JP, Hovingh GK, Stroes ES, Otvos JD, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150:84-93.
30. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
32. Salmela E, Lappalainen T, Fransson I, Andersen PM, Dahlman-Wright K, Fiebig A, Sistonen P, Savontaus ML, Schreiber S, Kere J, Lahermo P. Genome-wide analysis of single nucleotide polymorphisms uncovers population structure in Northern Europe. PLoS One. 2008;3:e3519.
33. Lao O, Lu TT, Nothnagel M, Junge O, Freitag-Wolf S, Caliebe A, Balascakova M, Bertranpetit J, Bindoff LA, Comas D, Holmlund G, Kouvatsi A, Macek M, Mollet I, Parson W, Palo J, Ploski R, Sajantila A, Tagliabracci A, Gether U, Werge T, Rivadeneira F, Hofman A, Uitter-linden AG, Gieger C, Wichmann HE, Rüther A, Schreiber S, Becker C, Nürnberg P, Nelson MR, Krawczak M, Kayser M. Correlation between genetic and geographic structure in Europe. Curr Biol. 2008;18: 1241-1248.
34. Novembre J, Johnson T, Bryc K, Kutalik Z, Boyko AR, Auton A, Indap A, King KS, Bergmann S, Nelson MR, Stephens M, Bustamante CD. Genes mirror geography within Europe. Nature. 2008;456:98-101.
35. Gigante B, Vikstrom M, Meuzelaar LS, Chernogubova E, Silveira A, Hooft FV, Hamsten A, De Faire U. Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels. Thromb Haemost. 2009;101:943-953.
36. Tall AR, Abreu E, Shuman J. Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. J Biol Chem. 1983;258:2174-2180.
37. Pussinen P, Jauhianinen M, Metso J, Tyynela J, Ehnholm C. Pig plasma phospholipid transfer protein facilitates HDL interconversion. J Lipid Res. 1995;36:975-985.
38. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993;268:4032-4036.
39. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem. 1993;268:23098-23105.
40. Colhoun HM, Taskinen MR, Otvos JD, van den Berg P, O'Connor J, van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein b-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes. 2002;51:3300-3305.
41. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, Tall AR. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med. 2001;7:847-852.
42. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Sadeghi-Niaraki F, van Tol A. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res. 2004;45:805-811.
43. Van Haperen R, van Tol A, van Gent T, Scheek L, Visser P, van der Kamp A, Grosveld F, de Crom R. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem. 2002;277:48938-48943.
44. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC. Increased atherosclerotic lesions in ApoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol. 2003;23:1601-1607.
45. Davey SG, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22.
46. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol. 2009;6:455-463.
47. Samyn H, Moerland M, Van Gent T, Van Haperen R, Grosveld F, Van Tol A, De Crom R. Elevation of systemic PLTP, but not macro-phage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 2009;204:429-434.